来那度胺联合硼替佐米和地塞米松治疗 多发性骨髓瘤的疗效

  • 打印
  • 收藏
收藏成功


打开文本图片集

中图分类号:R733.3 文献标志码:A DOI:10.11958/20250356

Abstract:ObjectiveTo investigate the eficacyoflenalidomide combined with bortezomibanddexamethasone in the treatmentof multiple myeloma (MM)and their efectson heat shock protein90(HSP90)mRNA,miR-28-5p,anti-tartrate acid phosphatase 5b(TRACP-5b)and highmobilitygroup protein B1(HMGB1).MethodsEighty patients with newly diagnosed MM wereselectedanddividedinto thetwo-combination group(4O patients treated with bortezomib and dexamethasone)and the three-combination group (40 patients treated with bortezomibanddexamethasone combined with lenalidomide)acording tothetreatmentmodalities.Real-timefluorescencequantitativepolymerasechainreactionwas used to detect HSP90 mRNA and miR-28-5p levels.Enzyme-linked immunosorbent asy was used to detect TRACP-5b and HMGB1 levels.The clinical eficacy of the2 groups was compared.Levels of HSP90 mRNA,miR-28-5p,TRACP-5b, HMGB1,theimmunecellfunction,renalfunction indexes and the incidence ofadversereactions were comparedbefore and aftertreatment.ResultsThetotaleffectiverateof thethree-combinationgroupwashigherthanthatofthetwo-combination groups (92.50% vs. 75.00% , P<0.05 ).Compared with the pretreatment, the levels of HSP9O mRNA,TRACP-5b,blood creatinie (SCr),andurea nitrogen (BUN)decreased inthe2 groupsafter treatment,and which waslower inthethreecombination group than that in the two-combination groups.The levels of miR-28-5p,HMGB1,CD 4+ ,CD3 + and CD4+/CD8+ were elevatedinthe2 groups,and the levels were higher inthethree-combination group thanthose inthetwo-combination group( P<0.05 ).There was no significant differencein the incidence of adverse reactions between the two groups. ConclusionLenalidomidecombined withbortezomibanddexamethasone is clinicalleffective,safeandreliable in the treatment of MM.

Keywords:multiplemyeloma; lenalidomide;bortezomib;dexamethasone;HSP9O heat-shockproteins;HMGB1 protein;miR-28-5p;tartrateresistantacidphosphatase5b isoenzyme

多发性骨髓瘤(multiple myeloma,MM)是一种血液系统恶性肿瘤,主要表现为贫血、肾损伤及骨痛等[1-2]。(剩余12076字)

monitor